Transcatheter Cardiovascular Therapeutics (TCT)

The Transcatheter Cardiovascular Therapeutics (TCT) conference is the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the largest conference focused on interventional cardiovascular medicine. TCT includes seminars on all areas of intervention cardiology, structural heart, vascular in interventions, peripheral artery disease, and other procedures in the cath lab.

Boston Scientific’s Agent Drug-Coated Balloon (DCB), which delivers a therapeutic dose of the anti-proliferative drug paclitaxel to the patient’s scar tissue to prevent ISR from recurring, gained FDA approval on March 1..

Cardiologists share historic research that led to FDA’s long-awaited approval of coronary DCB

When Boston Scientific’s coronary DCB gained approval in the United States, it was a moment the country's cardiologists had been looking forward to for years. The cardiologists who researched the device have now detailed their findings, highlighting the "unmet need" this technology is addressing. 

Carrie Redick RN MSN NEA-BC, director of interventional cardiology and structural heart, Morristown Medical Center, Atlantic Health System, explains the need for financial literacy among structural heart program directors at the Transcatheter Cardiovascular therapeutics (TCT) 2023 meeting.

Why financial literacy is so important for structural heart program directors

Carrie Redick, an ICU nurse for nearly 20 years, said understanding more about financial data improved her ability to acquire funding and other resources for her program when necessary. 

Video of Patricia Keegan, NP, Emory, explains value of the ACC TVT NCDR registry for TAVR and why it is important from both a quality monitoring standpoint and for attracting patients to your program.

Data registries have been a huge success for U.S. structural heart programs

ACC/STS National Cardiovascular Data Registry metrics reporting for TAVR is important for marketing and care quality, explains Patricia Keegan, NP, with the Emory Heart and Vascular Center.

CroíValve DUO device tricuspid valve

CroíValve kicks off early feasibility study for new TR device, names cardiologist Martin Leon to advisory board

The company hopes to enroll 15 patients to monitor the safety and effectiveness of its new-look transcatheter device for severe tricuspid regurgitation. 

Samin Sharma, MD, director of interventional cardiology and director of clinical cardiology, Mount Sinai Hospital, New York, discusses the first-in-human use of the Magenta Elevate percutaneous left ventricular assist device (pLVAD) with a small 10 French size and 5.5 liters per minute of hemodynamic support.

Initial results promising for world's smallest percutaneous heart pump

A new 10 French percutaneous heart pump could help greatly reduce vascular complications and improve cardiogenic shock outcomes.

Video of Yousif Ahmad, MD, Yale, discussing IVL advances and increased reinbursements

Tracking key advances in intravascular lithotripsy

Yousif Ahmad, MD, spoke with Cardiovascular Business about the latest advances in IVL therapy, including new reimbursement changes for the technology. 

Ziad Ali, MD, explaines the impact of coronary intravascular lithotripsy (IVL) use in nodular and eccentric calcium morphologies at TCT 2023. IVL was found to produce better outcomes than atherectomy or high pressure balloons. #TCT #TCT2023 #TCT23 #IVL

IVL is safe and effective across all calcium morphologies, new research confirms

Ziad Ali, MD, detailed two studies he presented on coronary intravascular lithotripsy at TCT 2023 in San Francisco.

Ramon Varcoe explains the LIFE-BTK trial for the Abbott Esprit fully bioresobable scaffold at TCT23.

Fully bioresorbable stents boost care for CLI patients in LIFE-BTK trial

Ramon Varcoe, MBBS, co-principal investigator for the LIFE-BTK trial, discussed the results with Cardiovascular Business at TCT 2023. "I can't wait to start using these in my patients. It's going to make a huge difference."